
    
      vaccination protocol to induce specific immune responses against melanoma associated antigens
      by intradermal injections of mRNA coding for the corresponding antigen. Antigens used are
      Melan-A, Mage-A1, Mage-A3, Survivin, GP100 and Tyrosinase. GM-CSF is used as an adjuvans.
      Phase I/II clinical trial to analyse safety and immune respones in stage III/IV melanoma
      patients.
    
  